Pre-clinical trials based on proprietary combination demonstrate significant suppressive effect on alcohol consumption TORONTO, May…
Preclinical study results demonstrated the combination of SciSparc’s CannAmide™ with Clearmind’s MEAI has the potential…
MELBOURNE, Australia, May 10, 2022 (GLOBE NEWSWIRE) — Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage…
Data from the completed Phase 1b/2 trial to be presented at the American Society of…
WARREN, N.J., May 10, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical…
Nes-Ziona, Israel, May 10, 2022 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
U.S. Food and Drug Administration (FDA) approval received for VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin)…
NEW ORLEANS, May 10, 2022 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo Bio” or the “Company”),…
TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq:…
Webinar on Tuesday, May 17, 2022 at 10:00 a.m. ET BRIDGEWATER, N.J., May 10, 2022…
– Facility in Alachua, Florida Is Expected to be Completed in the Fourth Quarter of…
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics…
Topline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected…
Prelude remains on track for clinical data readouts and next steps for the PRMT5 program,…
-Orally administered SYN-020 observed to be well tolerated across all doses in healthy volunteers- ROCKVILLE,…
XPro™ Promotes Remyelination in a Cuprizone Model of Multiple Sclerosis(MS) by Improving Macrophage Phagocytosis (clearing) of Myelin Debris…
DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) — NightHawk Biosciences (NYSE American: NHWK), a fully…
Botensilimab data to be presented and Phase 2 trials to launch. AGEN1571 (ILT2) clinical trials…
Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced…
Cystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program Topline data from cystic fibrosis (CF) Phase 2…